SCHEMBL2216236

SCHEMBL2216236

COc1ccccc1-c1ccc(-c2cc3ccnn3c(Nc3ccc(NC(=O)c4ccc(CN)cc4)cc3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.41
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 2/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 1/20 0.38
CASP3 P42574 1/20 0.38
RAB9A P51151 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
IDO1 P14902 2/20 0.38
TDO2 P48775 2/20 0.38
SNCA P37840 1/20 0.38
HPSE Q9Y251 1/20 0.38
KIT P10721 1/20 0.38
PDGFRA P16234 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
ALOX15 P16050 1/20 0.37
CASP1 P29466 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215236 0.88 HDAC1 (0.41) KLKB1KMT2AMEN1ALDH1A1MAPT
SCHEMBL2212378 0.88 SNCA (0.49) KLKB1KMT2AMEN1KDM4EALDH1A1
SCHEMBL2211981 0.88 HDAC1 (0.45) KLKB1KMT2AMEN1POLBMAPT
SCHEMBL2214847 0.87 NAMPT (0.45) HDAC1KDM1A
SCHEMBL2215189 0.87 PLAU (0.50) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL2215297 0.85 PTPN1 (0.45) KLKB1KMT2AMEN1ALDH1A1POLB
SCHEMBL2214607 0.85 PLAU (0.46) KMT2AMEN1KDM4EALDH1A1POLB
SCHEMBL2213866 0.85 PLG (0.47) KLKB1KDM4EALDH1A1MAPTSNCA
SCHEMBL2215216 0.84 PLAU (0.41) KLKB1KMT2AMEN1POLBMAPT
SCHEMBL2214976 0.84 MAPT (0.47) KMT2AMEN1KDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 KLKB1 3482/4885KMT2A 3645/4885MEN1 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.